In two studies with over 85% cirrhotic controls, the combination of DMMs with either AFP and AFP-L3 or AFP and gender improved sensitivity for early-stage HCC detection by 14–15% in the primary cohort, compared to the GALAD score alone [27, 28]. The gene discussed is AFP; the disease is hepatocellular carcinoma.